Fayez Sarofim & Co Buys 60,210 Shares of Intuitive Surgical, Inc. $ISRG

Fayez Sarofim & Co boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,169,350 shares of the medical equipment provider’s stock after purchasing an additional 60,210 shares during the quarter. Intuitive Surgical comprises about 1.2% of Fayez Sarofim & Co’s holdings, making the stock its 27th biggest position. Fayez Sarofim & Co owned 0.33% of Intuitive Surgical worth $528,207,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Norges Bank bought a new position in shares of Intuitive Surgical during the 2nd quarter worth about $2,569,260,000. Rakuten Investment Management Inc. acquired a new stake in shares of Intuitive Surgical in the 3rd quarter valued at about $388,436,000. Amundi increased its position in Intuitive Surgical by 29.7% in the 3rd quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock valued at $1,451,362,000 after buying an additional 739,444 shares in the last quarter. Vanguard Group Inc. increased its position in Intuitive Surgical by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock valued at $18,115,025,000 after buying an additional 670,302 shares in the last quarter. Finally, Sands Capital Management LLC raised its stake in Intuitive Surgical by 77.0% during the 3rd quarter. Sands Capital Management LLC now owns 1,341,109 shares of the medical equipment provider’s stock worth $599,784,000 after buying an additional 583,539 shares during the period. 83.64% of the stock is owned by institutional investors.

Insider Activity

In other Intuitive Surgical news, SVP Mark Brosius sold 2,362 shares of Intuitive Surgical stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $498.68, for a total transaction of $1,177,882.16. Following the transaction, the senior vice president directly owned 3,554 shares of the company’s stock, valued at $1,772,308.72. The trade was a 39.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Myriam Curet sold 421 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total transaction of $208,378.16. Following the completion of the sale, the executive vice president owned 409 shares of the company’s stock, valued at approximately $202,438.64. The trade was a 50.72% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 32,943 shares of company stock worth $17,279,568. Company insiders own 0.70% of the company’s stock.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: FDA clearance expands da Vinci 5 into cardiac surgery, opening a much larger long-term TAM (management cites a jump from ~17k to ~160k addressable procedures in cleared markets) — a multi-year growth driver for procedure volume and consumables. Read More.
• Positive Sentiment: Completed acquisition of Southern Europe distributor businesses (Italy, Spain, Portugal) shifts da Vinci and Ion sales to direct operations — should improve control of regional sales/service and capture margin/recurring revenue over time. Read More.
• Positive Sentiment: Sell-side momentum: Citigroup upgraded ISRG to Buy and several analysts maintain bullish price targets, supporting upside thesis and sentiment. Read More.
• Positive Sentiment: Recent Q4 results beat consensus (strong revenue and EPS growth), reinforcing recurring-consumables revenue and the upgrade cycle for da Vinci systems. Read More.
• Neutral Sentiment: Analyst consensus shows meaningful upside (Zacks highlights ~29.7% average target upside), but that depends on execution and multiple expansion remaining intact. Read More.
• Neutral Sentiment: Long-form bullish pieces reiterate a multi-year growth story from da Vinci 5, Ion and software/services but don’t change near-term valuation concerns. Read More.
• Negative Sentiment: Cybersecurity incident (phishing-linked breach affecting internal systems) is the immediate catalyst for the share decline — investors will watch for customer impact, data exposure, and remediation costs. Read More.
• Negative Sentiment: Insider selling (recent EVP share sales) and management guidance calling for a deceleration in worldwide da Vinci procedure growth in 2026 could pressure near-term sentiment and valuation. Read More. • Read More.

Intuitive Surgical Stock Down 1.5%

Shares of Intuitive Surgical stock opened at $472.16 on Monday. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $603.88. The business has a 50 day moving average price of $513.26 and a 200-day moving average price of $512.96. The company has a market cap of $167.68 billion, a PE ratio of 59.84, a price-to-earnings-growth ratio of 3.64 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The company had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. During the same quarter in the previous year, the firm earned $2.21 earnings per share. Intuitive Surgical’s quarterly revenue was up 18.8% on a year-over-year basis. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ISRG. Citigroup raised Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 price objective for the company in a research note on Wednesday, March 11th. Zacks Research raised Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 19th. TD Cowen upgraded Intuitive Surgical to a “strong-buy” rating in a report on Tuesday, January 27th. Barclays set a $712.00 price target on shares of Intuitive Surgical and gave the company an “overweight” rating in a research report on Monday, January 26th. Finally, UBS Group set a $570.00 price objective on shares of Intuitive Surgical and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus price target of $615.86.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.